Information on efficacy and predictors of response to Adalimumab ( Humira ) in ulcerative colitis clinical practice is limited.
The aim of study was assessed the response to Adalimumab and its predictors in an observational cohort study.
Retrospective cohort study based on data obtained from ENEIDA registry. All patients diagnosed with ulcerative colitis treated with Adalimumab were included.
Response to Adalimumab was evaluated at weeks 12, 28, and 54 according to the partial Mayo score, and requirement of colectomy until end of follow-up.
48 patients with ulcerative colitis treated with Adalimumab were included; 39 ( 81.3% ) had previously received Infliximab ( Remicade ).
Response rates at weeks 12, 28 and 54 were 70.8%, 43.2% and 35% respectively.
Response to prior treatment with Infliximab was the only predictive factor of response to Adalimumab at week 12, which was obtained in 90% of Infliximab remitters, 53.8% of responders and 33.3% of primary non-responders ( p=0.01 ).
Colectomy was required in 11 patients ( 22.9% ), after a mean time of 205 days.
The only clinical independent predictor of colectomy was non-response to Adalimumab at week 12: colectomy rates were 5/34 ( 14.7% ) in responders and 6/14 ( 42.9% ) in non-responders ( p=0.035 ), time free of colectomy was significantly reduced in non-responders ( p=0.01 ).
Adalimumab withdrawal due to adverse events occurred in 4.2% of patients.
In conclusion, this study has shown that Adalimumab is an effective treatment in patients with ulcerative colitis.
If used as a second anti-TNF, previous achievement of remission with the first anti-TNF predicts response, and failure to achieve response at week 12 predicts colectomy. ( Xagena )
García-Bosch O et al, J Crohns Colitis 2013;7:717-722